UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 2, 2011 (January 28,
2011)
SINOBIOMED
INC.
(Exact
name of registrant as specified in its charter)
Commission
File Number 333-128399
|
Delaware
|
20-1945139
|
|
|
(State
or other jurisdiction
of
incorporation)
|
(I.R.S.
Employer
Identification
No.)
|
Room
4304, 43/F China Resources Building
26
Harbour Road, Wan Chai
Hong
Kong HKSAR
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: 011-852-2511-0238
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
ITEM
5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS
On
January 28, 2011, Mr. Chris Metcalf resigned as Chairman and a Director of
Sinobiomed Inc. (the “Company”) effective immediately without any disagreement
with the Company on any matter relating to the Company’s operations, policies or
practices.
In
addition, on January 28, 2011, Mr. George Yu was appointed as a Director of
Sinobiomed, which fills the vacancy created by the resignation of Mr. Chris
Metcalf.
Mr. Yu,
age 38, is currently the President and CEO of the Company since September 1,
2010, and has over 15 years of management and corporate development
experience. Prior to his appointment, he served, from September 2009
to August 2010, as the Managing Partner, Bay2Peak S.A., a financial advisory and
investment management firm, and from September 2005 to August 2009, as the
Managing Partner of Bay2Peak Strategies, Ltd., a financial advisory and
investment management firm, where he was responsible in both instances for the
sourcing and execution of transactions, including financings, mergers and
acquisitions, and investor relations. Prior to that, Mr. Yu served in
various operational management and consulting roles and has worked with
small-cap hedge and venture capital funds in emerging markets and investment
banking at Lehman Brothers. Mr. Yu holds a Bachelor of Science Degree
from the University of Tuebingen, Germany, and a Masters in Business
Administration, cum laude, in Finance and Economics from the Columbia Business
School.
Mr. Yu is
not, and has not been, a participant in any transaction with the Company that
requires disclosure under Item 404(a) of Regulation S-K. There is no
family relationship between Mr. Yu and any director, executive officer, or
person nominated or chosen by the Company to become a director or executive
officer.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
SINOBIOMED
INC.
|
|||
|
By:
|
/s/
George Yu
|
||
|
Name:
|
George
Yu
|
||
|
Title:
|
Chief
Executive Officer and Director
|
||
Date:
February 2, 2011
3